Validation of Rat Endometriosis Model by Using Raloxifene as a Positive Control for the Evaluation of Novel SERM Compounds
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Approximately 10% of women of reproductive age suffer from endometriosis, a potentially painful disease process and important cause of female infertility. Raloxifene, a commercially available SERM (selective estrogen receptor modulator) compound, used for the treatment of postmenopausal osteoporosis, has preclinically demonstrated its estrogen antagonist effect on uterine tissue in rats. There is potential that SERM compounds may become a viable treatment option for human endometriosis, although more investigation is needed. In this study, raloxifene was administered at various doses to determine the efficacy and an appropriate dose level for use as a positive control in a rat model of endometriosis. Prior to dose administration, all rats underwent a bilateral ovariectomy, autologous transplantation of uterine tissue onto the peritoneal surface of the abdominal wall, and implantation of a subcutaneous estrogen pellet (E2). Two separate postsurgical experiments were performed. In experiment 1, following a 4-wk recovery, the rats bearing implants were assigned to three groups: (1) removal of the E2 pellet and dosing vehicle only (n = 7); (2) E2 and vehicle (n = 6); and (3) E2 and raloxifene at 10.0 mg/kg (n = 6). In experiment 2, also following a 4-week recovery, the rats bearing implants were assigned to five groups (n = 8/group): (1) E2 and vehicle only; (2) E2 and raloxifene, 0.3 mg/kg/d; (3) E2 and raloxifene, 1.0 mg/kg/d; (4) E2 and raloxifene, 3.0 mg/kg/d; (5) E2 and raloxifene, 10.0 mg/kg/d. All rats were dosed orally BID for 14 d. At the end of the study, the implanted endometrium was remeasured and compared to the pretreatment measurement. The results from both studies demonstrated that Raloxifene at only one dose (10.0 mg/kg) displayed significant implant regression (p < .05). Subsequently, our rat endometriosis experimental model consistently uses the exogenous E2 pellet and raloxifene at 10 mg/kg, BID, as a positive control to help screen and compare novel SERM compounds.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tested in animal studies RLX induces regression of endometriosis implant [270, 271].”
From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [270]
In the citing paper
“Raloxifene and bazedoxifene both result in lesion regression and inhibition of proliferation in murine models (Yao et al., 2005;Kulak et al., 2011;Naqvi et al., 2014).”
From Endometriosis and nuclear receptors (2019) · cites this paper as Yao et al., 2005
Citations
Cites
Studies on the surgical induction of endometriosis in the rat.
Vernon, M. W., & Wilson, E. A. (1985) · Fertility and Sterility · doi:10.1016/s0015-0282(16)48988-0 · Cited by 482
Clinical Effects of Raloxifene Hydrochloride in Women
Khovidhunkit, W., & Shoback, D. M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-5-199903020-00015 · Cited by 159
Endometriosis: novel etiopathogenetic concepts and clinical perspectives
Vignali, M., Infantino, M. S., Matrone, R., Chiodo, I., Somigliana, E., Busacca, M., & Viganò, P. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)03233-8 · Cited by 130
Okada, H., Heya, T., Ogawa, Y., & Shimamoto, T. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24466-4 · Cited by 116
Rajkumar, K., Schott, P. W., & Simpson, C. W. (1990) · Fertility and Sterility · doi:10.1016/s0015-0282(16)53532-8 · Cited by 65
Buelke‐Sam, J., Bryant, H. U., & Francis, P. C. (1998) · Reproductive Toxicology · doi:10.1016/s0890-6238(98)00003-3 · Cited by 54
BASIC RESEARCH IN ENDOMETRIOSIS
Sharpe-Timms, K. L. (1997) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(05)70304-1 · Cited by 45
Effect of the selective estrogen receptor modulator raloxifene on explanted uterine growth in rats
Swisher, D. K., Tague, R. M., & Seyler, D. E. (1995) · Drug Development Research · doi:10.1002/ddr.430360107 · Cited by 20
Zanagnolo, V. L., Beck, R., Schlaff, W. D., Damewood, M. D., Bobbie, D., & Rock, J. A. (1991) · Fertility and Sterility · doi:10.1016/s0015-0282(16)54137-5 · Cited by 16
Research works printed but not linked: 2
- Littman B A, 1995, Principles and Practice of Endocrinology and metabolism, 2nd ed., 906
- Okada H, 1987, J Pharmacol Exp Ther, 244, 744
Cited by
Endometriosis is a chronic systemic disease: Clinical challenges and novel innovations
Taylor, H. S., Kotlyar, A. M., & Flores, V. A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00389-5 · Cited by 1,425
Progesterone and Estrogen Signaling in the Endometrium: What Goes Wrong in Endometriosis?
Marquardt, R. M., Kim, T. H., Shin, J.-H., & Jeong, J.-W. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153822 · Cited by 491
Hormonal treatments for endometriosis: The endocrine background
Vannuccini, S., Clemenza, S., Rossi, M., & Petraglia, F. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09666-w · Cited by 336
Chen, Y., Li, H., Huang, C., Twu, N., Yen, M., Wang, P., Chou, T., Liu, Y., Chao, K., & Yang, M. (2010) · The Journal of Pathology · doi:10.1002/path.2761 · Cited by 245
Endometriosis and nuclear receptors
Yilmaz, B. D., & Bulun, S. E. (2019) · Human Reproduction Update · doi:10.1093/humupd/dmz005 · Cited by 243
Metadata
- Authors
- Yao, Z., Shen, X., Capodanno, I., Donnelly, M., Fenyk-Melody, J., Hausamann, J., Nunes, C., Strauss, J., & Vakerich, K.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- Journal of Investigative Surgery
- Publisher
- Informa UK Limited
- Published
- 2005-01
- Volume
- 18
- Issue
- 4
- Pages
- 177-183
- ISSN
- 0894-1939 (ISSN-L)
- 1521-0553
- OpenAlex
- W1965260226
- Cited by
- 60
- References
- 9
- Citations by year
- 2024: 3 · 2023: 3 · 2022: 4 · 2021: 6 · 2019: 5 · 2018: 7 · 2017: 2 · 2016: 1 · 2015: 1 · 2014: 5 · 2013: 2 · 2012: 4
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Investigative Surgery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Effects and risks of endocrine disrupting chemicals
- Keywords
- endometriosis, rat endometriosis model, raloxifene, selective estrogen receptor modulators, positive control, dose selection, drug screening, female infertility, antiestrogens, ovariectomy, estrogen receptor antagonism, endometriosis treatment
- MeSH terms
- Animals, Disease Models, Animal, Endometriosis, Endometrium, Female, Organ Size, Rats, Sprague-Dawley, Selective Estrogen Receptor Modulators, Raloxifene Hydrochloride, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Validation of Rat Endometriosis Model by Using Raloxifene as a Positive Control for the Evaluation of Novel SERM Compounds. https://app.cochat.ai/papers/10.1080/08941930591004412
- The paper
- Yao, Z., Shen, X., Capodanno, I., Donnelly, M., Fenyk-Melody, J., Hausamann, J., Nunes, C., Strauss, J., & Vakerich, K. (2005). Validation of Rat Endometriosis Model by Using Raloxifene as a Positive Control for the Evaluation of Novel SERM Compounds. Journal of Investigative Surgery. https://doi.org/10.1080/08941930591004412
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.